Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2015

View Archived Issues

Phase I study shows promising results for GS-5745 in patients with advanced solid tumors

MEDI-0639 shows preliminary evidence of antitumor activity

IDRI studies ID-93 + GLA-SE vaccine following completion of TB treatment

Circadian Technologies begins phase I study of OPT-302 in wet AMD

CEA-targeted cytokine targets tumoral cells and shows immmune activity in tumor site

Chimerix patents antiviral agents

NIH grant supports GeoVax's clade C HIV vaccine development program

Nanobiotix starts phase I/II trial of NBTXR-3 in liver metastasis and hepatocellular cancer

TES Pharma and Ecole Polytechnique Federale de Lausanne collaborate on kynurenine pathway modulators

LG Life Sciences discloses a novel GPR120 agonist

First patient dosed in seliciclib trial in Cushing's disease

Taisho divulges OX-1 and -2 antagonists

Lycera introduces F1F0-ATPase inhibitors

New study shows promising activity of LSD1 inhibitor RN-1 for sickle cell disease

ESN-364, an optimized NK3 receptor antagonist for sex-hormone disorders

Biogen and AGTC collaborate to develop gene-based therapies for ophthalmic diseases

Antitumor agent Farydak approved in Japan

FDA accepts IND for MAGE-A10 T for NSCLC

Innate Pharma and IPC collaborate on translational research for immune checkpoint inhibitors

Xiaflex approved in Japan for Dupuytren's contracture

Acoalan approved in Japan

McGill University patents anti-GD cancer vaccine

Dicerna Pharmaceuticals develops DsiRNAs targeting TTR for amyloidosis

S. aureus vaccine in early development at Evaxion Biotech

Federal grants support research at University of Pittsburgh on mosquito-borne viruses

Targovax confirms closing of the acquisition of Oncos Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...